Zimbabwe has rejected a significant US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' insistence on confidential data.
The decision became public after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesman later clarified that the United States was demanding access to health data for research and commercial gain but refused to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further talks to secure a deal suitable to both sides so the nation's critical HIV programme can continue.
Broader Implications
This development follows a similar situation in neighbouring Kenya, where a court blocked a similar health funding agreement after concerns were raised about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and responsibility.
Based on statements, Sixteen African countries have so far agreed to these new health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our people if a new health crisis emerge."
National Interest and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were upending frameworks previously set up through the international organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This framework is designed to guarantee that when a nation provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration could be arranged in a manner that honours the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts said it understood the official position, but suggested that negotiations must proceed considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it added.
This impasse emphasises the ongoing challenges between receiving vital international aid and protecting local interests in an increasingly data-driven world.